{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:31:18Z","timestamp":1789104678796,"version":"build-2803163510"},"reference-count":17,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.270757","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:20:14Z","timestamp":1771521614000},"page":"926-928","source":"Crossref","is-referenced-by-count":2,"title":["Differential Response to\n                    <sup>177<\/sup>\n                    Lu-PSMA-617 in Patients with Tumor Suppressor GeneMutated Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Abigail","family":"Pepin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek K.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara N.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel U.","family":"Takvorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia R.","family":"OBrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Mankoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipose G.","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026060105301021000_67.6.926.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026060105301021000_67.6.926.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"2026060105301021000_67.6.926.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256263"},{"key":"2026060105301021000_67.6.926.4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci."},{"key":"2026060105301021000_67.6.926.5","unstructured":"Schaeffer EM Srinivas S Adra N . NCCN guidelines: prostate cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1459. Accessed February 10, 2026."},{"key":"2026060105301021000_67.6.926.6","doi-asserted-by":"crossref","first-page":"e2400645","DOI":"10.1200\/PO-24-00645","article-title":"Cancer-control outcomes of patients with metastatic castration-resistant prostate cancer with BRCA gene or tumor suppressor mutations undergoing 177-lutetium prostate-specific membrane antigen radioligand therapy","volume":"8","author":"Wenzel","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2026060105301021000_67.6.926.7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41391-024-00814-2","article-title":"Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients","volume":"28","author":"Dasari","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2026060105301021000_67.6.926.8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers17040645","article-title":"TP53 deficiency in the natural history of prostate cancer","volume":"17","author":"Ofner","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026060105301021000_67.6.926.9","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1038\/s41598-021-86681-6","article-title":"TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells","volume":"11","author":"Anbalagan","year":"2021","journal-title":"Sci Rep."},{"key":"2026060105301021000_67.6.926.10","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.7150\/thno.96322","article-title":"Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"14","author":"Slootbeek","year":"2024","journal-title":"Theranostics."},{"key":"2026060105301021000_67.6.926.11","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2024.42.16_suppl.5008","article-title":"Baseline ctDNA analyses and associations with outcomes in taxane-nave patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore [abstract]","volume":"42","author":"De Bono","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026060105301021000_67.6.926.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5"},{"key":"2026060105301021000_67.6.926.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026060105301021000_67.6.926.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.1882"},{"key":"2026060105301021000_67.6.926.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.011"},{"key":"2026060105301021000_67.6.926.16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41391-021-00424-2","article-title":"Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer","volume":"25","author":"Priv","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2026060105301021000_67.6.926.17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","volume":"28","author":"Armstrong","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:34Z","timestamp":1785269914000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.270757"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270757","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}